CeQur Simplicity

CeQur® Marks 10 Million Mealtime Injections Replaced and Highlights Commercial Expansion

Christy Owenby — Wed, 18 Jun 2025 06:00:31 +0000

CeQur announces that its wearable insulin patch, CeQur Simplicity, has replaced 10 million mealtime insulin injections. The company continues its momentum with expanded clinical access and key leadership appointments.

CeQur^®, maker of the wearable insulin patch CeQur Simplicity, today announced a major milestone in its mission to simplify mealtime insulin delivery. Since launch, CeQur Simplicity has helped patients avoid 10 million mealtime insulin injections, a powerful reflection of growing adoption and the device’s impact on simplifying diabetes management.

Managing diabetes remains a complex and demanding challenge for millions. Multiple daily injections (MDI), often required for mealtime insulin, can disrupt routines, burden emotional and physical health, and interfere with social and work life. On average, people on mealtime insulin require more than 1,000 injections each year. Yet:

72% of patients report not taking insulin outside the home.ⁱ
57% admit to missing injections they knew they should take.ⁱⁱ

CeQur Simplicity was created to change that. The discreet, wearable patch simplifies mealtime insulin by eliminating the need for multiple daily injections making it easier to dose anytime, anywhere. In real-world experience, patients saw significant improvement in glycemic control, including an average reduction in A1C of 1.29% and an average improvement of time-in-range (TIR) of 27%.ⁱⁱⁱ

To support continued growth and ensure more patients benefit from this breakthrough solution, CeQur has strategically expanded its commercial organization by adding top-tier sales leadership and significantly growing its Clinical Diabetes Specialist team.

In March 2025, Darin Row joined CeQur as Vice President of Sales. Darin brings over two decades of diabetes-focused and product launch experience having previously served in leadership roles at Lilly, Amylin, and most recently Dexcom. As someone living with diabetes himself, Darin brings a deeply personal understanding to his role—driving his commitment to building a high-performing team that keeps the patient perspective at the center of every decision.
Janelle Duffee, BSN, RN, PHN, CDCES, joined CeQur in 2024, bringing over 25 years of diabetes experience, including leadership roles at Insulet. As Director of Clinical Education, she has played a key role in expanding CeQur’s Field-Based Clinical Diabetes Specialist (CDS) Team, which now offers more than 300 years of combined clinical diabetes expertise. In addition, a team of virtual CDSs provides patients with access to support across all U.S. time zones, seven days a week.

CeQur has seen how CeQur Simplicity is meaningfully improving the mealtime insulin experience. Here is what patients are saying about the real-world impact of CeQur Simplicityⁱⁱⁱ:

“I really love this patch. My A1C is down to 7.5 and it has really helped me. I’m at the point where I don’t think I could live without it.”
“Such a great tool. I just recently started using it, and it’s a game-changer. I have been able to stay in a healthy blood glucose range for longer in a day. And it’s so simple to use!”

References:

i. Grabner M, Chen Y, Nguyen M, Abbott SD, Quimbo R. Using observational data to inform the design of a prospective effectiveness study for a novel insulin delivery device. Clinicoecon Outcomes Res. 2013;5:471-479.
ii. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240-245.
iii. Data on file.

CeQur Closes a $120M Equity Financing to Drive Commercial Growth

Christy Owenby — Tue, 07 Jan 2025 06:00:42 +0000

The financing secured will drive growth and accelerate commercial expansion efforts, support the scaling of commercial teams and outreach initiatives to bring CeQur Simplicity, its 4-day wearable insulin delivery device, to more healthcare providers and patients managing diabetes.

CeQur^®, a medical device company dedicated to simplifying insulin delivery for individuals on multiple daily injections, today announced the successful close of a $120 million financing round. This significant investment underscores the confidence in CeQur’s mission to simplify the lives of people managing diabetes.

The funds will support the continued commercial expansion of CeQur Simplicity, the company’s innovative 4-day wearable insulin delivery device. CeQur will continue to grow its Sales Force and expand its Clinical team to ensure that more people living with diabetes can benefit from convenient, discreet, and injection-free dosing.

“We are grateful for the support of our investors as we accelerate our mission to transform diabetes care,” said Brad Paddock, President and CEO of CeQur. “This financing will enable us to reach more patients, expand our commercial footprint, and continue innovating solutions that simplify mealtime insulin management”, said Mike Rubino, CFO of CeQur.

CeQur has seen growing adoption of its CeQur Simplicity patch, a discreet, easy-to-use bolus insulin delivery solution, with over 6,000 patients currently using the device.

CeQur continues to increase and improve pharmacy access. In addition to the more than two thirds of commercially insured patients on formulary, CeQur has reached agreements with numerous Medicare Part-D and State Medicaid programs. Overall, better than 80% of all claims are being covered as a pharmacy benefit. The average copay is less than $45/month.

Related to manufacturing, CeQur’s 40,000 sq/ft automated cleanroom facility completed all of its qualifications in Q4 2024. The facility is scheduled to manufacture commercial product in 2025.

CeQur Simplicity™, a Wearable Mealtime Insulin Delivery Device, Obtains FDA-Clearance for 4 Days of Wear to Further Simplify Diabetes Management

Christy Owenby — Tue, 18 Jun 2024 06:30:47 +0000

The CeQur Simplicity patch is now FDA-cleared for up to 4 days of wear. Each patch replaces up to 12 injections further simplifying mealtime insulin management.

We’re excited to announce the FDA’s recent 510(k) clearance of CeQur Simplicity for an extended wear duration from 3 to 4 days. This update marks an advancement in mealtime insulin management to the longest wearable insulin delivery patch, providing people with diabetes discretion, additional convenience, and injection-free dosing.

A pivotal analysis of over 26,000 people with Type 2 Diabetes (T2D) on Multiple Daily Injections (MDI) from the IQVIA database indicated that only 21.3% achieved the ADA-recommended A1C goal of less than 7%.i This study represents a large portion of insulin users and >90% of people with T2D on multiple daily injections who are still using pens or syringes. This data also underscores the need for more effective insulin delivery solutions like CeQur Simplicity, which now, with its extended 4-day wear time, aims to improve dosing adherence and simplify diabetes management even further.

The new 4-day clearance for CeQur Simplicity represents a significant improvement, increasing the device’s wear time by 33% and reducing the number of applications. Each patch now replaces up to 12 mealtime injections, equating to over 1000 less injections annually, offering a substantial benefit for individuals managing diabetes.

This extended wear time underscores CeQur’s commitment to improving the lives of those managing diabetes, offering more freedom and flexibility. CeQur Simplicity, with the promise of “Mealtime Insulin, Simplified,” provides a discreet and easy-to-use solution for those seeking an alternative to traditional mealtime insulin injections. With this clearance, CeQur Simplicity sets itself apart as a unique, bolus-only insulin therapy, promoting better adherence and an enhanced quality of life. Recent real-world studies have demonstrated 94% patient satisfaction and an average A1C reduction of 1.29%.ii, iii

“We are excited to share that there are now ~5000 people with diabetes using CeQur Simplicity for their mealtime insulin delivery,” said Bradley Paddock, President and CEO at CeQur. “With the 4-day clearance, we hope to make it even easier for people with diabetes to take their mealtime insulin.”

This extension is built on the success of the initial launch and the positive reception from users who have experienced the benefits of the 3-day wear patch. In response to growing demand, CeQur has successfully increased its manufacturing capacity with a fully automated manufacturing line to support 100,000 patients and is increasing the size of its sales force, ensuring wider accessibility and support for the diabetes community.

“Our Market Access team has been working diligently, and as a result of their activities, nearly 70% of commercial lives are on formulary coverage and more are being added regularly,” Chris Arapoff, VP of Health Economics & Reimbursement, reported. The average patient’s copay is now less than $40/month.

CeQur will showcase the 4-day wear CeQur Simplicity insulin patch at the American Diabetes Association’s 84th Scientific Sessions in Orlando. Attendees are invited to Booth #1223 for demonstrations and to learn more about the impact of this innovative diabetes management solution.

References:

Shah, V. et al, 2024. Obesity and Disparity in Glycemic Outcomes are Prevalent Among Adults with Type 2 Diabetes (T2D) on Multiple Daily Injections (MDI) of Insulin: A Large US Retrospective Cohort Study. Poster presented at ATTD 2024 poster #532. March 6-9. Florence, Italy
Isaacs, D., Kruger, D., Shoger, E., Chawla, H., Patient Perceptions of Satisfaction and Quality of Life Regarding Use of a Novel Insulin Delivery Device, Clinical Diabetes , 2023;41(2):198–207
Data on File at CeQur
Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association’s 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA
Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B. 2019. Implementation of Basal–Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.
Bergenstal R., et al Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles; Journal of Diabetes Science and Technology 1–7, 2021

CeQur Appoints Rick Doubleday and Dr. Meret Gaugler to Board of Directors

superadmin — Fri, 25 Jun 2021 01:46:41 +0000

CeQur_®, a medical device company committed to simplifying the lives of people with diabetes by revolutionizing insulin-delivery solutions, today announced the appointments of Rick Doubleday and Meret Gaugler, Ph.D., to its Board of Directors.

Click here to download the press release.

CeQur Raises $115 Million Series C5

Christy Owenby — Tue, 13 Apr 2021 20:08:04 +0000

CeQur Raises $115 Million Series C5 Financing to Support Commercialization and Scale-Up of Automated Manufacturing for CeQur Simplicity Wearable Insulin-Delivery Device

CeQur®, a medical device company committed to simplifying the lives of people with diabetes by revolutionizing insulin-delivery solutions, today announced the close of an oversubscribed $115 million equity financing. The company will use the funds to advance commercial plans for CeQur Simplicity, including market development activities, a phased commercial launch strategy that includes a limited market release in 2021, and the scale-up of high-volume manufacturing. CeQur Simplicity is both FDA cleared and CE-marked.

Click here to download the press release.

“High Treatment Satisfaction with 3-day Insulin Patch is Independent of Patient Demographics: A Post-Hoc Analysis” — a presentation at the American Diabetes Association 80th Scientific Sessions

Christy Owenby — Tue, 16 Jun 2020 20:36:59 +0000

Presentation preview: . Click here to download the presentation.

The Wider View: With new CEO in place, CeQur primed to PAQ a punch in diabetes market

Christy Owenby — Thu, 06 Jun 2019 20:40:34 +0000

Click here to open an external link.

ATTENTION:

You will be leaving CeQur’s website. CeQur does not control the content of the website you are visiting.

CeQur Appoints Bradley Paddock Chief Executive Officer

Christy Owenby — Wed, 05 Jun 2019 20:16:00 +0000

CeQur_® announced that the company has appointed Bradley Paddock as chief executive officer, effective today. Paddock brings a track record of commercial medtech successes, notably leading sales up to $600 million during his eight-year tenure at Kyphon, Inc. Paddock also managed successful commercial operations for multiple industry-leading companies, including Stryker, Bausch + Lomb, Inc., and Medtronic, Inc.

CeQur Appoints Peter B. Luther to Board of Directors

Christy Owenby — Mon, 18 Mar 2019 20:24:27 +0000

CeQur_® announced the appointment of Peter B. Luther to its board of directors, effective immediately. Luther is a 29-year veteran of the medical device and diagnostics, OTC drugs and consumer-packaged goods industries.

Click here to download the press release.

Two New ‘Wearable Pen’ Insulin Devices Coming Soon

Christy Owenby — Thu, 19 Jul 2018 20:45:59 +0000

Click here to open an external link.

ATTENTION: You will be leaving CeQur’s website. CeQur does not control the content of the website you are visiting.